| |
|
|
|
Fifth Annual Conference for the Organisation for
Oncology and Translational Research was held in Macau, China on the
20th and 21st of February 2009 at the Fisherman's Wharf Convention
and Exhibition Centre.
The theme of the conference was on Anti-Cancer Strategy. We provided
to the participants not only the most up-to-date knowledge in the
area of breast cancer and colorectal cancer therapeutics, but also
an open discussion on hot research topics including the application
of translational research to the clinic, as well as development of
therapeutic paradigm. Renowned international experts have been assembled
to provide an outstanding program not only for the clinicians but
also scientists involved in the field.
 Back
to events list
 |
Nadir Arber
Head of Integrated Cancer
Prevention Center
Tel Aviv Sourasky Medical Center, Israel
Professor Arber obtained MD from Hebrew University, Hadassah School
of Medicine in 1987. He was also granted BSc in 1982 and MHA in
1991. After his postgraduate training/research including fellowships
(1993-1996 at Columbia university in New York, he assumed a position
of Associate Professor of Medicine at Sackler School of Medicine,
Tel Aviv University in 1996. He has been Professor of Medicine
and Gastroenterology at Sackler School of Medicine, Tel Aviv University
since 2002 and concurrently holds other positions at various institutions.
He is the incumbent of the Yechiel and Helen Lieber Chair for
Cancer Research, and the head of the integrated cancer prevention
center.
Prof. Arber is a member of many national and international societies
including American Association for Cancer Research and sits on
board of various associations, such as CHS International Educational
Cancer Prevention Conference. Additionally, he is a reviewer an
editorial board members of many medical/academic journals. Professor
Arber has published more than 300 papers of review and chapters
and received more than 90 grants and awards. |
|
 |
Ahmad Awada
Jules Bordet Institute
Brussels, Belgium
Professor Ahmad Awada was born in Lebanon and studied Medicine
at the Free University in Brussels (ULB), Belgium. He did a specialisation
in Internal Medicine and Medical Oncology at Jules Bordet Institute
(under the supervision of Professor Jean Klastersky), in Brussels,
until 1992 ("La plus grande distinction"). During his specialisation,
he also followed trainings in the clinical development of new
therapies and new anticancer drugs, under the supervision of Professor
Martine Piccart.
To deepen his training, he stayed in the Netherlands (New Drug
Development Office, Free University, Amsterdam;) and in San Antonio,
USA (Institute for Drug Development, under the direction of Professor
D. Von Hoff). He focused on the clinical development of new anticancer
agents.
Back from the USA at the beginning of 1994, Doctor Awada became
Assistant Head of Medical Oncology Clinic, and Head of the New
Drugs Development Unit at Jules Bordet Institute, Brussels. Since
April 2005, he is the Head of the Medical Oncology Clinic. He
has an important clinical activity in the treatment of solid tumors.
Doctor Awada took an active part in the development of new drugs,
some of them already widely used.
Thanks to the recent progress in technology and computer sciences,
and consequently in molecular biology, we can understand better
now how a cancer cell works and how it becomes a cancer cell.
Many drugs are now studied to block this process. Those are the
molecular-targeted therapies, a subject studied extensively in
clinical research by Doctor Awada and were the basis for this
thesis obtained from the ULB, Brussels, in 2004.
The aim of Doctor Awada, as far as research is concerned, is to
look for new active anticancer drugs in solid tumors (new cytotoxics
and molecular targeted therapies), and to individualize the treatments
according to the tumor characteristics.
|
|
 |
Yihai Cao
Professor in Vascular Biology
Microbiology and Tumor Biology Center, Karolinska Institutet,
Sweden
Yihai Cao is a professor of vascular biology at the Karolinska
Institute in Stockholm, Sweden. He received an M.D. degree
from Shandong University, Medical School and a Ph.D. degree
from the Karolinska Institute. After receiving his Ph.D.
degree in molecular biology in 1993, Dr. Cao continued his
postdoctoral training in Dr. Judah Folkmans laboratory
at the Harvard Medical School where he was promoted as an
instructor in 1995. In 1996, Dr. Cao returned to the Karolinska
Institute and held competitive positions of assistant and
associate professors. In 2004, he was promoted as a full
professor at the Karolinska Institute. Dr. Cao is a recipient
of several awards including the Swedish Fernstroms prize
and the Fulbright award. Dr. Cao also received a honorary
medical doctoral degree from the Copenhagen University,
Denmark. Dr. Cao holds a guest professorship from many universities
in China.
Dr. Cao is an expert in tumor angiogenesis research. His
laboratory focuses on translational oncology research by
understanding the mechanisms underlying tumor angiogenesis
and by defining novel therapeutic targets. He was one of
the team members in the Folkman's lab that discovered the
first endogenous specific angogenesis inhibitor-angiostatin.
Following this initial finding, Dr. Cao discovered that
other kringle structures have antiangiogenic features. For
example, he discovered Kringle 5 as an important angiogenesis
inhibitor. He was the first one to describe that polyphenols
in tea and other functional foods are important groups of
angiogenesis inhibitors.
Another major theme of Dr. Cao's research is to understand
the complexity of interplay between tumor derived angiogenic
factors. They found that tumor-derived angiogenic factors
could positively and negatively communicate each other to
promote tumor angiogenesis, growth and metastasis. These
findings demonstrate that combinatorial therapy consisting
several antiangiogenic agents with different mechanistic
principles would be more effective. It is also important
to overcome therapy escape of antiangiogenic drugs and drug-resistant
issues.
Dr. Cao's recent studies show that tumor-derived angiogenic
factors could induce systemic cancer syndrome including
paraneoplatic syndrome and cancer cachexia. For example,
tumor-produced VEGF induces severe anemia, ascites, hepatomegaly,
splenomegaly, and endocrine disorders. Surprisingly, anti-VEGFR
agents significantly prolong life-time of tumor bearing
mice without affecting tumor growth. These findings provide
the first evidence that "off" tumor targets are crucial
for prolonging life time in tumor-bearing animals. Dr. Cao's
work suggests that improvement of tissue/organ functions
by anti-VEGF agents could be one of the mechanisms underlying
survival benefits of these targeted anti-cancer drugs.
Dr. Cao has made significant contributions to the field
of lymphangiogenesis, which is crucial for mediating lymphatic
metastasis. They have identified several important lymphangiogenic
factors that mediate lymphatic metastasis, thus defining
novel therapeutic targets for prevention and treatment of
cancer metastasis.
Dr. Cao's current research interests include development
of novel antiangiogenic agents for the treatment of cancer
and metastasis. Based on their recent findings, a novel
antiangiogenic compound has been identified as an orally
active and potent anti-cancer agent. They are now developing
in vivo systems to study the role of angiogenesis in facilitating
the early events of cancer metastasis.
|
|
 |
Louis W.C. Chow
Executive Director,
OOTR
Honorary Professor, Li Ka Shing Faculty of Medicine, HKU
Honorary Professor, NingXia Medical College, China
Louis W.C. Chow is a Medical Director of the Comprehensive
Centre for Breast Diseases at the UNIMED Medical Institute
in Hong Kong, Executive Director of the Organisation for Oncology
and Translational Research in Hong Kong, Honorary Clinical
Professor of the Clinical Trial Centre at the University of
Hong Kong, Honorary Professor of the Ningxia Medical College
School of Clinical Medicine in Ningxia, China, Honorary Professor
at Tohoku University in Sendai, Japan and Honorary Consultant
of Kiang Wu Hospital in Macao. Dr. Chow also holds positions
of the Honorary Secretary at the Hong Kong Academy of Medicine,
the Steering Committee Member on e-Health Record Sharing of
the Food and Health Bureau, the Government of the HKSAR, the
Task Group Member on Breast Cancer Management of Hospital
Authority in Hong Kong, as well as the immediate past President
of the Asian Breast Cancer Society.
Dr. Chow received his medical education at the University
of Hong Kong and completed his residency at the Queen Mary
and Kwong Wah Hospitals in Hong Kong. Following this, he underwent
sabbatical trainings at Memorial Sloan-Kettering Cancer Center
in New York, Yale University in New Haven, Connecticut, and
the University of Southern California in Los Angeles. After
his trainings in surgical oncology, Dr. Chow returned to the
University of Hong Kong and held competitive positions of
Assistant and Associate Professors at Department of Surgery
of the University. Since November 2008, he has been appointed
as an Honorary Clinical Professor at the University of Hong
Kong. During his professorship, he gave lectures to medical
and nursing students as well as staff on breast cancer surgical
and medical treatments, and directed the Radioguided Surgery
Courses for Breast Cancer and a Minimally Invasive Breast
Biopsy Course at the University. Apart from his clinical and
teaching duties, in the University, he also served as an Associate
Dean of the Faculty of Medicine, a Deputy Director of Centre
of Education and Training at Department of Surgery, and examiners
for postgraduate examinations as well as supervisors of doctorate
and master degree students.
Dr. Chow is a Fellow of the Royal College of Surgeons, Fellow
of the College of Surgeons of Hong Kong, and Fellow of the
American Cancer Society. He is also an expert in cancer research
and has obtained a patent on a mouse cell line derived from
human malignant cystosarcoma phylloides. In the past few years,
he obtained different research and professional grants for
cancer research purposes in the University and contributed
as Principal Investigators/Co-investigators of several international
clinical trials. Dr. Chow has published over 110 articles
in peer-reviewed journals. His key research interests are
breast cancer molecular therapy, chemoresistance, chemoprevention
and translational research in breast cancer.
|
|
 |
Aaron Ciechanover
Laureate of Nobel
Prize in Chemistry 2004 
Distinguished Research Professor, Faculty of Medicine,
the Technion Israel Institute of Technology, Haifa
Professor Aaron obtained his M.Sc. (1970) and M.D. (1974)
from "Hadassah" and the Hebrew University School of Medicine,
Jerusalem and D.Sc. (1981) from Faculty of Medicine, Technion-Israel
Institute of Technology, Haifa in Israel. He has received
several Academic Awards, including Nobel Prize in Chemistry
in 2004. He also has won several Academic Honors as well as
Sir Hans Krebs Medal (FEBS) an every year since 2004, he has
been awarded Honorary Doctorate or Professor in various universities.
He also received Honorary Citizenship many times including
from City of Lima, Peru.
Prof. Aaron has begun his lecture in various institutes since
1979 after going through his clinical training for 7 years
(1973-1979) in "Rambam" University Medical Center. Between
1974 and 1977, he was also a member of National Compulsory
Service, Israel Defense Forces. Since 1992 he began his professorship
in Department of Biochemistry, Faculty of Medicine, Technion-Israel
Institute of Technology while assuming a position of Director
(1993-2000) in The Rappaport Family Institute for Research
in the Medical Sciences. He also contributed in various academic
places in USA, Japan, and Sweden as Visiting Professor.
|
|
 |
Giampietro Gasparini
Division of Medical Oncology, Azienda Ospedaliera
"San Filippo Neri", Rome, Italy
Giampietro Gasparini obtained his degree in medicine at the
faculty of medicine and surgery at the university of Padua
in 1980. Subsequently, he specialized in oncology, clinical
pharmacology and radiotherapy. He was a fellow at the "Istituto
Nazionale per la Ricerca e la Cura dei Tumori" of Milan, medical
assistant at the "Centro di Riferimento Oncologico" of Aviano
and then vice-director of the Division of Medical Oncology
at the General Hospital of Vicenza. In 1997, professor Gasparini
was appointed as the head and founder of the Oncology at the
Azienda Ospedaliera "Bianchi-Malacrino-Morelli" in Reggio
Calabria, and sequently as Director of the Department of Oncology.
Presently, Gasparini is director of the Division of Medical
Oncology at the Azienda Ospedaliera "San Filippo Neri" in
Rome. Gasparini is the author of more than 280 publications
in peer-reviewed journals and more than 320 abstracts at scientific
conferences and meetings. The personal impact factor and the
citation index up to June 2008 are 750 and >5404, respectively.
Finally, he is a member of the editorial board of 18 international
oncological journals; recipient of national awards and reviewer
for several journals and scientific organizations.
|
|
 |
Rakesh Kumar
The Catherine Birch McCormick Endowed Chair Professor and Chairman
Department of Biochemistry and Molecular Biology
The George Washington University School of Medicine
Washington, D.C., USA
Professor Rakesh Kumar is currently the Catherine Birch McCormick
Chair at the George Washington University Medical Center,
where he is Professor and Chairman of the Department of Biochemistry
and Molecular Biology. Professor Kumar received his PhD degree
in Biochemistry from All India Institute of Medical Sciences
in New Delhi, in 1984. After spending a year there, he moved
to New York City in 1986 as a Postdoctoral Fellow in Molecular
Biology Program at the Sloan-Kettering Institute. Upon completing
his fellowship, he was named an Assistant and Associate Lab
Members at the Sloan-Kettering Institute. In 1992, he went
to the Penn State University College of Medicine as an Associate
Professor. After 4 years there, he relocated to the M. D.
Anderson Cancer Center Houston, where he was Professor and
Deputy Chairman of the Department of Molecular and Cellular
Oncology and holding the John G. and Marie Stella Kenedy Memorial
Foundation Chair until January 2009 when he moved to the George
Washington University.
Prof. Kumar's research is directed at defining the phenotypic
signaling leading to cancer progression with a particular
focus on cytoskeleton signaling and p21-activated kinases
(PAKs). His laboratory has provided evidence of a definitive
role of PAK1 in cancer cell invasiveness, discovered PAK1
physiologic substrates responsible for various cellular activities,
and identified nuclear localization and functions of PAK1.
Collectively, these discoveries paved the way for PAKs to
be identified as cancer therapeutic target by the pharmaceutical
industry. Prof. Kumars work has earned 12 Cover Illustrations
in the major Cancer Research Journals. He has received several
awards and honors for his research excellence including, the
2004 MDA Faculty Achievement Award in Basic Sciences, the
2004 Norman Brinker Award for Research Excellence, and the
2006 Ranbaxy Research Award in Pharmaceutical Sciences. Prof.
Kumar has authored over 200 peer-reviewed research papers
and reviewed articles published in leading scientific journals
and several book chapters, and he has served as Editor for
the book Molecular Signaling and Therapeutics and NR Coregulators
in Human Diseases. Prof. Kumar serves on the editorial boards
of leading cancer and biochemical journals, including Cancer
Research, for which he is a Senior Editor.
|
|
 |
Per Eystein Lønning
Professor of Oncology
Haukeland University Hospital, Norway
Professor Per Eystein Lønning gained MD from the University
of Bergen and in 1979 and PhD in 1989. He became certified
as specialist in Therapeutic Oncology and Radiotherapy in
1988 and as a Professor in Oncology in 1992.
Prof. Lønning has been employed at Haukeland University
Hospital since 1982 and is now a Professor of Oncology at
Haukeland University Hospital and at University of Bergen.
He spent about one and a half years as a Research Fellow in
Norwegian Cancer Society from 1984 and one year as Clinical
Research Registrar in Department of Medicine and Academic
Biochemistry at Royal Marsden Hospital (London and Surrey)
in 1988-1989. Prof. Lønning has been a member of Steering
Committee in Norwegian Breast Cancer Group from 1989 and Co-Director
of the Hospital Program on Gene Therapy from 1999. He is a
member of the Editorial board for several international medical
journals. Prof. Lønning has published more than 250
papers. His key research interests are endocrine therapy and
chemoresistance in breast cancer.
|
|
 |
Hope S. Rugo
Professor of Medicine, Division of Hematology and Oncology
Comprehensive Cancer Center, University of California San Francisco, USA
Hope Rugo, MD is a Clinical Professor of Medicine in the Division
of Hematology and Oncology at the University of California
San Francisco (UCSF), Comprehensive Cancer Center, where she
directs the Breast Cancer Clinical Trials Program. Her research
interests include novel therapies for advanced breast cancer,
evaluation of circulating endothelial and epithelial cells
as novel markers of response and resistance to therapy, complementary
medicine and supportive care.
Dr Rugo is an investigator in the Bay Area Spore at UCSF Breast
Cancer Center, and the principal investigator of a number
of clinical trials. She has published many peer-reviewed papers
and has given presentations on a variety of cancer related
topics. Dr Rugo is a member of the CALGB breast core and the
symptom control subcommittee.
After graduating summa cum laude from Tufts University, Dr
Rugo went on to recieve her medical degree from the University
of Pennsylvania School of Medicine and completed both a residency
in internal medicine and fellowship in hematology and oncology
at the UCSF. Additionally, she completed a two-year post-doctoral
fellowship in immunology at Stanford University.
|
|
 |
Hironobu Sasano
Professor, Department of Pathology
Tohoku University School of Medicine, Japan
Professor Sasano obtained his MD from Tohoku University School
of Medicine, Japan in 1982. He then began three years of postgraduate
research and training, two years of which he spent as a Fulbright
Exchange Research and Clinical Fellow at Cornell Medical Center
in New York, USA. After obtaining his postgraduate qualification
from Tohoku University, Prof. Sasano moved to Washington D.C.,
USA, where he worked for three years as a resident at the
George Washington University Hospital.
Prof. Sasano returned to Japan in 1989, when he began his
professorship in Department of Pathology at Tohoku University
School of Medicine, while also working as an attending pathologist
at the university hospital. Since 1988, he has been Professor
and Director of the Department of Pathology. Prof. Sasano
is a member of various academic societies and sits on the
editorial board of several international journals. His main
area of research is steroid biosynthesis, metabolism and action.
|
|
 |
Yan Sun
Academician, Chinese Academy of Engineering
Professor of Clinical Oncology, Chinese Union Medical University, China
Steering Committee President, Chinese Society of Clinical Oncology
President, Asian Clinical Oncology Society
Professor SUN Yan, a famous medical oncologist, was graduated
from Yenching University with a B.S. degree in 1951 and from
Peking Union Medical College with a M.D. degree in 1956. Prof.
Sun studied traditional Chinese medicine from 1960 to 1961,
and worked, between 1979 and 1980, as a visiting professor
in M. D. Anderson Cancer Center, USA. Since 1959, he has been
working in the Department of Medical Oncology in Cancer Hospital
of Chinese Academy of Medical Sciences (CAMS), holding the
post of professor & director of Department of Medical
Oncology from 1986 to 1994. He was also honored as the "Outstanding
Physician" by CAMS and Peking Union Medical College in
1993, designated as an "Advanced Worker" in national
health care system by the Ministry of Human Affairs in 1994,
and elected an Academician of Chinese Academy of Engineering
in 1999.
Prof. Sun is now a professor of clinical oncology of Chinese
Union Medical University, the director of the National GCP
Center for Anticancer Agents and New Drug and Clinical Research
Base of State Drug Administration, the vice-chairman of Chinese
Foundation for Cancer Research, the member of WHO Expert Advisory
Panel on Cancer and senior member of UICC, the director of
International Society of Chemotherapy, the leaguer of International
Association of Lung Cancer Research and American Society of
Clinical Oncology, the Chairman of Instructional Committee
of Chinese Society of Clinical Oncology, and member of editorial
board of 26 domestic and 6 international journals. His name
was entered in the Cambridge "International Who' Who
in Medicine" since 1986. Recently, he was chosen as the
president elect of Asian Society of Clinical Oncology (ACOS,
with the tour of duty starting from 2006) and the 7th international
conference of ACOS convention in 2006 in Beijing.
Extracted from
Chin J Integr Med 2005; l l(4): 303-304
|
|
 |
Masakazu Toi
Professor, Department of Surgery,
Kyoto University, Japan
President, OOTR
Professor Toi received his MD in 1982 from Hiroshima University
in Japan. He worked as a resident and a surgical oncologist
before obtaining his PhD from Hiroshima University School
of Medicine in 1988 when he reached to the position of Head
for Breast Research Group in Department of Surgical Oncology
at the same hospital.
Prof. Toi moved to Tokyo Metropolitan Cancer and Infectious
Diseases Center, Komagome Hospital in 1992 and contributed
as Director in various laboratory and division for 14 years
until 2006. Since 2003, he has also been Professor of Drug
Delivery System Center of Science University of Tokyo and
shared his study in the University of Hong Kong and Tokyo
as well. He assumed a position of Professor in Department
of Surgery, Graduate School of Medicine in Kyoto University
in 2007. Dr. Toi is on the Board of several national societies
and has been appointed reviewer several journals and organizations.
He has published many peer-reviewed articles and has received
several national and international awards.
|
|
 |
Benjamin C.Y. Wong
The Simon Lee Professor in Gastroenterology
The University of Hong Kong, Hong Kong
Benjamin Wong is currently the Professor at the Department
of Medicine, University of Hong Kong in Hong Kong, and Director
of the S. K.Y. Lee Digestive Disease Center of Queen Mary
Hospital. Professor Wong attended the University of Hong Kong
where he completed his MBBS in 1989. He then attended the
Department of Medicine, University of Hong Kong where he gained
his training.
His particular research interests are Helicobacter pylori-related
diseases, functional gastrointestinal problems including gastro-esophageal
reflux disease and non-cardiac chest pain, and prevention
and screening of gastric and colon cancer. Dr. Wong also leads
a team of scientists in the research of apoptosis-related
genes in gastric and colon cancer.
Professor Wong is a committee member of a number of professional
organizations, including the Practice Parameters Committee
of American College of Gastroenterology, the Colorectal Cancer
Screening Committee of the World Organisation of Digestive
Endoscopy (OMED), the Guideline and Publication Committee
of the World Gastroenterological Organisation (WGO-OMGE),
the Hong Kong Society of Gastroenterology, and Chairman of
the Research Committee of the Hong Kong Digestive Foundation.
He has published 14 book chapters, 240 original articles and
260 conference proceedings. He is the editor of the Journal
of Gastroenterology and Hepatology, Associate Editor-in-chief
of the Chinese Journal of Gastroenterology and serves as a
member of the editorial boards of several international and
national journals.
|
|
 |
Binghe Xu
Drug Evaluation Specialist, State Food and Drug Administration
Chief Division of Breast Cancer, Department of Medical Oncology,
Cancer Hospital, Chinese Academy of Medical Sciences
Director, Laboratory of Clinical Pharmacology, National GCP Center
Professor Xu obtained his doctoral degree in 1999 from the
Chinese Peking Union Medical College and is now the Professor
of Medical Oncology. He worked and received training at Department
of Medical Oncology in Miami University, USA from August 1991
to October 1993. In 1994, he was promoted to Associate Division
Chief at Department of Medical Oncology in Chinese Academy
of Medical Sciences; in 1998, he was further promoted to Division
Chief.
Prof. Xu has worked on clinical research in medical oncology
for many years and his research focuses on systemic therapy
for operable breast cancer, therapies for metastatic breast
cancer, novel anti-cancer agents as well as clinical trials.
Besides, he is experienced in systemic therapy for lung cancer,
lymphoma, gastrointestinal cancer, bone and soft tissue sarcoma.
During his training in US, he worked a lot on multi-drug resistance.
He now sits on about 10 editorial boards of local important
journals.
|
|
 |
Yosef Yarden
The Weizmann Institute of Science, Israel
Professor Yosef Yarden, of the Department of Biological Regulation
at the Weizmann Institute of Science, Rehovot, received his
BSc in biology and geology (cum laude) from the Hebrew
University, Jerusalem, Israel in 1979, and his PhD from the
Weizmann Institute in 1985. He trained at Genentech Inc. in
San Francisco and in the Massachusetts Institute of Techonology
(Cambridge, MA) before establishing his own research laboratory
in 1989 at the Weizmann Institute. Currently, Prof. Yarden
is the Dean of the Feinberg Graduate School, Chair of the
National Committee on Biotechnology and Chair of the Research
Committee of the Israel Cancer Association. In the past he
served as Vice President for Academic Affairs of the Weizmann
Institute of Science, Dean of the Faculty of Biology and Director
of the M.D. Moross Cancer Research Institute.
Prof. Yarden has received numerous awards for his work, including
the H. Dudley Wright Research Award in Biomembranes, the Somech
Sachs Prize in Chemistry, the Andre Lwoff Prize, the Lombroso
Award for Cancer Research, the Michael Bruno Prize of Yad
Hanadiv Fund, the Teva Founder's Prize, an the MERIT Award
of the U.S. National Cancer Institute. Yarden is a member
of Israel Academy of Sciences and Humanities, the European
Molecular Biology Organization and the Asia-Pacific International
Molecular Biology Network.
|
|
Day 1 - 20th
February 2009
|
|
|
Session
I: Colorectal Cancer |
|
Speaker |
|
| |
Insights into the
molecular biology and genetics of colorectal cancer |
|
Yosef Yarden |
|
| |
Contemporary practices in colorectal cancer management: From
adjuvant therapy to metastatic disease |
|
Nadir Arber |
|
|
|
|
| |
|
|
|
|
| |
Session
II: Breast Cancer |
|
Speaker |
|
| |
Pharmacogenetics
in breast cancer |
|
Giampietro Gasparini |
|
| |
Angiogenesis
and cancer therapy: From research to clinical application |
|
Yihai Cao |
|
| |
Prognostic and predictive factors in
early breast cancer |
|
Hironobu Sasano |
|
| |
Evolution
in endocrine adjuvant therapy for early breast cancer |
|
Per E. Lønning |
|
| |
Sequence and duration
of endocrine therapy in postmenopausal breast cancer patients:
An overview |
|
Hope S. Rugo |
|
|
|
|
| |
|
|
|
|
| |
PRIME
Oncology Luncheon Symposium: Breast Cancer in 2009 and Beyond:
Practical Solutions for Important Issues |
|
| |
Multidisciplinary
management of early breast cancer in China: Current challenges
|
|
Louis W.C. Chow |
|
| |
Debate:
Management of early endocrine responsive postmenopausal
breast cancer in the near future will include upfront extended
duration (>5 years) adjuvant aromatase inhibitor therapy and
adjuvant use of a bisphosphonate |
|
| |
Pro:
Hope S. Rugo |
Contra:
Per Eystein Lønning |
|
|
|
|
|
|
|
| |
Clinical
Case #1: Metastatic breast cancer following adjuvant
anthracycline and taxane |
|
Binghe Xu |
|
| |
Debate:
Gene array profiles are superior to conventional prognostic/predictive
factors to assist in management of early endocrine responsive
breast cancer |
|
| |
Pro: Louis
W.C. Chow |
Contra:
Hironobu Sasano |
|
|
|
|
|
|
| |
Clinical
Case #2: Management of progressive metastatic
HER2 amplified disease after initial response to trastuzumab-based
therapy |
|
Ahmad Awada |
|
|
|
|
| |
|
|
|
|
| |
Session
IIIa: Colorectal Cancer |
|
Speaker |
|
| |
Advances in clinical
and molecular diagnosis |
|
Nadir Arber |
|
| |
Novel and emerging molecularly targeted therapies |
|
Nadir Arber |
|
| |
New trials and
chemoprevention in Asia |
|
Benjamin C.Y. Wong |
|
|
|
|
| |
Session
IIIb: BreastCancer |
|
Speaker |
|
| |
Novel biomarkers
|
|
Rakesh Kumar |
|
| |
Drug resistant bresat cancer |
|
Nadir Arber |
|
| |
New trials and
chemoprevention in Asia |
|
Louis W.C. Chow |
|
|
|
|
Day 2 - 21st February
2009
|
|
|
Session IV:
Selected Oral Abstract |
|
|
|
| |
Selected oral abstract presentations
|
|
|
|
|
|
|
| |
|
|
|
|
| |
Session V:
Keynote Lecture |
|
|
|
| |
New aspects of
ubiquitin mediated intracelluar protein degradation related
to cancer pathogenesis and therapy |
|
| |
Aaron
Ciechanover, MD, DSc, Laureaute of the Nobel Prize
in Chemistry, Technion-Israel Institute of Technology Rappaport
Institute, Haifa, Israel |
|
|
|
|
| |
|
|
|
|
| |
Session VIa:
Colorectal Cancer |
|
Speaker |
|
| |
Concepts in prevention and
screening in colorectal cancer |
|
Nadir Arber |
|
|
|
|
| |
Session IIIb:
BreastCancer |
|
Speaker |
|
| |
Concepts in HER-2 amplified
breast cancer |
|
Yosef Yarden |
|
|
|
|
|
Top
